GSK grabs FDA OK for new shingles vaccine, which will now tackle a key Merck franchise
Watch out Merck. GlaxoSmithKline is coming for a chunk of your shingles vaccine franchise.
Late on Friday the FDA announced that it had green-lighted Shingrix, one of its biggest development programs from the company’s vaccines group. Together with the new COPD three-in-one combo Trelegy Ellipta — approved in September — and an HIV therapy headed to a likely approval, Shingrix represents one of GSK’s best shots at carving our significant new revenue for itself from new products.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.